HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein

Atherosclerosis

Volumn 133, Issue 1, 1997, Pages 51-59

  Sakai, Masakazu ^a   Kobori, Shozo ^a   Matsumura, Takeshi ^a   Biwa, Takeshi ^a   Sato, Yoshihiro ^a   Takemura, Toru ^a   Hakamata, Hideki ^a   Horiuchi, Seikoh ^a   Shichiri, Motoaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Foam cell; HMG CoA reductase inhibitor; Macrophage growth; Simvastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; PRAVASTATIN; SIMVASTATIN; SQUALENE;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; ENDOCYTOSIS; ENZYME ACTIVITY; FOAM CELL; HUMAN; HUMAN CELL; MACROPHAGE FUNCTION; OXIDATION; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

EID: 0030810427     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00118-4     Document Type: Article

References (50)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
3. Gordon D, Reidy MA, Benditt EP, Schwartz SM. Cell proliferation in human coronary arteries. Proc Natl Acad Sci USA 1990;87:4600-4.
4. Rosenfeld ME, Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 1990;10:680-7.
5. Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis 1991;88:87-92.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
7. Yui S, Sasaki T, Miyazaki A, Horiuchi S, Yamazaki M. Induction of murine macrophage growth by modified LDLs. Arterioscler Thromb 1993;13:331-7.
8. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, Shichiri M, Horiuchi S. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994;269:31430-5.
9. Sato Y, Kobori S, Sakai M, Higashi T, Matsumura T, Morikawa W, Terano Y, Miyazaki A, Horiuchi S, Shichiri M. Lipoprotein (a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-b activation. Atherosclerosis 1996;125:15-26.
10. Sakai M, Miyazaki A, Hakamata H, Sato Y, Matsumura T, Kobori S, Shichiri M, Horiuchi S. Lysophosphatidylcholine potentiates the mitogenic activity of modified low density lipoprotein for human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1996;16:600-5.
11. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25.
12. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91:83-7.
13. Cuthbert JA, Lipsky PE. Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation. J Biol Chem 1990;265:18568-75.
14. Schmidt RA, Schneider CJ, Glomset JA. Evidence for post-translational incorporation of a product of mevalonic acid into Swiss 3T3 cell proteins. J Biol Chem 1984;259:10175-80.
15. Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R. Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-bis(2-chloroethyl)-N-nitrosourea and β -interferon on human glioma cells. Cancer Res 1992;52:4348-55.
16. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-9.
17. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993;13:571-8.
18. Bocan TMA, Mazur MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, Creswell MW, Lee H, Uhlendorf PD, Roth BD, Newton RS. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994;111:127-42.
19. Zhu BQ, Sievers RE, Sun YP, Isemberg WM, Parmley WW. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992;19:246-55.
20. Gellman J, Ezekowitz MD, Sarembock IJ, Azarin MA, Nochomowitz LE, Lerner E, Haudenschild CC. Effect of lovastatin on intimai hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-9.
21. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-8.
22. Miyazaki A, Sakai M, Suginohara Y, Hakamata H, Sakamoto Y, Morikawa W, Horiuchi S. Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J Biol Chem 1994;269:5264-9.
23. Shinohara M, Miyazaki A, Shichiri M, Morino Y, Horiuchi S. Exposure of rat peritoneal macrophages to acetylated low density lipoprotein results in release of plasma membrane cholesterol. J Biol Chem 1992;267:1603-8.
24. 2+-mediated oxidation. FEBS Lett 1992;314:199-202.
25. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K, Seo H. Involvement of β2-microglobulin modified with advanced glycation endo products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994;93:521-8.
26. Hakamata H, Miyazaki A, Sakai M, Suginihara Y, Sakamoto Y-I, Horiuchi S. Species difference in cholesteryl ester cycle and HDL-induced cholesterol efflux from macrophage foam cells. Arterioscler Thromb 1994;14:1860-5.
27. Fogelman AM, Haberland ME, Seager J, Hokom M, Edwards. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages. J Lipid Res 1981;22:1131-41.
28. Miyazaki A, Sakai M, Yamaguchi E, Sakamoto Y, Shichiri M, Horiuchi S. Two independent macrophage receptors for acetylated high-density lipoprotein. Biochem Biophys Acta 1993;1170:143-50.
29. Heider JG, Boyett RL. The picomol determination of free and total cholesterol. J Lipid Res 1978;19:514-8.
30. McFarlane AS. Efficient trace-labeling of proteins with iodine. Nature 1958;182:53.
31. Hakamata H, Miyazaki A, Sakai M, Sakamoto Y, Matsuda H, Kihara K, Horiuchi S. Differential effects of an acyl-coenzyme A: cholesterolacyltransferase inhibitor on HDL-induced cholesterol efflux from rat macrophage foam cells. FEBS Lett 1995;363:29-32.
32. Faust JR, Luskey KL, Chin DJ, Goldstein JL, Brown MS. Regulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cells. Proc Natl Acad Sci USA 1982;79:5205-9.
33. Sakai M, Miyazaki A, Hakamata H, Kodama T, Suzuki H, Kobori S, Shichiri M, Horiuchi S. The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation. J Biol Chem 1996;271:27346-52.
34. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992;95:87-94.
35. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin: the relation ship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 1992;209:315-9.
36. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, Horiuchi S. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 1992;43:667-70.
37. Quesney-Huneeus V, Galick HA, Siperstein MD. The role of mevalonate in cell cycle. J Biol Chem 1983;258:378-85.
38. Quesney-Huneeus V, Wiley MH, Siperstein MD. Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 1979;76:5056-60.
39. Habenicht AJR, Glomset JA, Ross R. Regulation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3T3 cells stimulated to divide by platelet-derived growth factor. J Biol Chem 1980;255:5134-40.
40. Fairbanks KP, Witte LD, Goodman DS. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 1984;259:1546-51.
41. Wolda SL, Glomset. Evidence for modification of lamin B by a product of mevalonic acid. J Biol Chem 1988;263:5997-6000.
42. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 1993;260:1937-42.
43. Maltese WA, Sheridan KM. Isoprenylated proteins in cultured cells: subcellular distribution and changes related to altered morphology and growth arrest induced by mevalonate deprivation. J Cell Physiol 1987;133:471-81.
44. Casey PJ, Solsky PA, Der CJ, Buss JE. p21ras Is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989;86:8323-7.
45. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989;57:1167-77.
46. Kawata S, Naqgase T, Yamasaki E, Ishiguro H, Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994;69:1015-20.
47. Schafer WR, Kim R, Sterne R, Thorner J, Kim S-H, Rine J. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and human. Science 1989;245:379-85.
48. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
49. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook G. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992;41:229-35.
50. Pentikainen P, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, Rogers JD. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992;32:136-40.